Journal of Clinical Pediatrics >
Diagnosis, treatment and future of children type 1 diabetes mellitus
Received date: 2022-03-27
Online published: 2022-05-13
Type 1 diabetes mellitus (T1DM) is the major type of pediatric diabetes. According to the longitudinal epidemiology surveys in our national large metropolitans, the average annual incidence increasing rate is about three times higher that the average in the world, and the incidence increase in children under five years ranks the top, which indicates the younger trend of T1DM. The etiology and underlying mechanism of T1DM is complicated, with genetic susceptibility and environmental trigger factors as the main causes of T1DM. Early onset, long-term of disease course and poor glycemic control result in high incidence of chronic diabetic complications, and affect psychomotor development. Drug therapy, blood glucose monitoring, diabetes education, exercise and nutrition therapy are the fundamental measures for good glycemic control in pediatric T1DM. Artificial pancreas, stem cell islet differentiation and transplantation, and immune intervention may fundamentally improve the treatment and prognosis of T1DM in the future.
Key words： type 1 diabetes mellitus; diagnosis; therapy; child
Feihong LUO . Diagnosis, treatment and future of children type 1 diabetes mellitus[J]. Journal of Clinical Pediatrics, 2022 , 40(5) : 321 -327 . DOI: 10.12372/jcp.2022.22e0411
| [1] | Rawshani A, Sattar N, Franzén S, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study[J]. Lancet, 2018, 392(10146): 477-486. |
| [2] | Patterson CC, Karuranga S, Salpea P, et al. Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Diabetes Atlas, 9th edition Diabetes Res[J]. Clin Pract, 2019, 157: 107842. |
| [3] | Knip M. Type 1 diabetes in Finland: past, present, and future[J]. Lancet Diabetes Endocrinol, 2021, 9(5): 259-260. |
| [4] | Piffaretti C, Mandereau-Bruno L, Guilmin-Crepon S, et al. Trends in childhood type 1 diabetes incidence in France, 2010-2015 [J]. Diabetes Res Clin Pract, 2019, 149: 200-207. |
| [5] | Flint SA, Gunn AJ, Hofman PL, et al. Evidence of a plateau in the incidence of type 1 diabetes in children 0-4 years of age from a regional pediatric diabetes center; Auckland, New Zealand: 1977-2019[J]. Pediatr Diabetes, 2021, 22(6): 854-860. |
| [6] | Fu H, Shen SX, Chen ZW, et al. Shanghai, China, has the lowest confirmed incidence of childhood diabetes in the world[J]. Diabetes Care, 1994, 17(10): 1206-1208. |
| [7] | Zhao Z, Sun C, Wang C, et al. Rapidly rising incidence of childhood type 1 diabetes in Chinese population: epidemiology in Shanghai during 1997-2011 [J]. Acta Diabetol, 2014, 51(6): 947-953. |
| [8] | Wu HB, Zhong JM, Hu RY, et al. Rapidly rising incidence of Type 1 diabetes in children and adolescents aged 0-19 years in Zhejiang, China, 2007 to 2013 [J]. Diabet Med, 2016, 33(10): 1339-1346. |
| [9] | Liu C, Yuan YC, Guo MN, et al. Incidence of type 1 diabetes may be underestimated in the Chinese population: evidence from 21.7 million people between 2007 and 2017[J]. Diabetes Care, 2021, 44(11): 2503-2509. |
| [10] | Nishioka Y, Noda T, Okada S, et al. Incidence and seasonality of type 1 diabetes: a population-based 3-year cohort study using the National Database in Japan Incidence and seasonality of type 1 diabetes: a population-based 3-year cohort study using the National Database in Japan[J]. BMJ Open Diabetes Res Care, 2020, 8(1): e001262. |
| [11] | Krischer JP, Lynch KF, Lernmark A, et al. Genetic and environmental interactions modify the risk of diabetes-related autoimmunity by 6 years of age: the TEDDY study[J]. Diabetes Care, 2017, 40(9): 1194-1202. |
| [12] | Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children[J]. JAMA, 2013, 309(23): 2473-2479. |
| [13] | Norris JM, Johnson RK, Stene LC. Type 1 diabetes-early life origins and changing epidemiology[J]. Lancet Diabetes Endocrinol, 2020, 8(3): 226-238. |
| [14] | Zhi D, Sun C, Sedimbi SK, Luo F, et al. Killer cell immunoglobulin-like receptor along with HLA-C ligand genes are associated with type 1 diabetes in Chinese Han population[J]. Diabetes Metab Res Rev, 2011, 27(8): 872-877. |
| [15] | Zhi D, Shen S, Luo F, et al. SNPs in the exons of Toll-like receptors are associated with susceptibility to type 1 diabetes in Chinese population[J]. Hum Immunol, 2014, 75(11): 1084-1088. |
| [16] | Pei Z, Chen X, Sun C, et al. A novel single nucleotide polymorphism in the protein tyrosine phosphatase N22 gene (PTPN22) is associated with type 1 diabetes in a Chinese population[J]. Diabet Med, 2014, 31(2): 219-226. |
| [17] | Zhu M, Xu K, Chen Y, et al. Identification of novel T1D risk loci and their association with age and islet function at diagnosis in autoantibody-positive T1D individuals: Based on a Two-Stage Genome-Wide Association Study[J]. Diabetes Care, 2019, 42(8): 1414-1421. |
| [18] | Sanjeevi S, Sun C, Kanungo A, et al. Killer immuno-globulin receptor genes and their HLA-C ligand are associated with Type 1 diabetes in an Eastern Indian population[J]. Diabet Med, 2016, 33(1): 91-96. |
| [19] | Frederiksen B, Kroehl M, Lamb MM, et al. Infant exposures and development of type 1 diabetes mellitus: The Diabetes Autoimmunity Study in the Young (DAISY)[J]. AMA Pediatr, 2013, 167(9): 808-815. |
| [20] | Lamb MM, Miller M, Seifert JA, et al. The effect of childhood cow's milk intake and HLA-DR genotype on risk of islet autoimmunity and type 1 diabetes: The Diabetes Autoimmunity Study in the Young[J]. Pediatr Diabetes, 2015, 16(1): 31-38. |
| [21] | Stene LC, Oikarinen S, Hyöty H, et al. Enterovirus infection and progression from islet autoimmunity to type 1 diabetes: The Diabetes and Autoimmunity Study in the Young (DAISY)[J]. Diabetes, 2010, 59(12): 3174-3180. |
| [22] | Vehik K, Lynch KF, Wong MC, et al. TEDDY Study Group. Prospective virome analyses in young children at increased genetic risk for type 1 diabetes[J]. Nat Med, 2019, 25(12): 1865-1872. |
| [23] | Vlad A, Serban V, Timar R, et al. Increased incidence of type 1 diabetes during the COVID-19 pandemic in Romanian children[J]. Medicina (Kaunas), 2021, 57(9): 973. |
| [24] | Unsworth R, Wallace S, Oliver NS, et al. New-onset type 1 diabetes in children during COVID-19: multicenter regional findings in the U.K.[J]. Diabetes Care, 2020, 43(11): e170-e171. |
| [25] | Tittel SR, Rosenbauer J, Kamrath C, et al. Did the COVID-19 lockdown affect the incidence of pediatric type 1 diabetes in Germany?[J]. Diabetes Care, 2020, 43(11): e172-e173. |
| [26] | Tapia G, Størdal K, Mårild K, et al. Antibiotics, acetaminophen and infections during prenatal and early life in relation to type 1 diabetes[J]. Int J Epidemiol, 2018, 47(5): 1538-1548. |
| [27] | Papadopoulou-Marketou N, Chrousos GP, Kanaka-Gantenbein C. Diabetic nephropathy in type 1 diabetes: a review of early natural history, pathogenesis, and diagnosis[J]. Diabetes Metab Res Rev, 2017, 33(2). doi: 10.1002/dmrr.2841. |
| [28] | Donaghue KC, Marcovecchio ML, Wadwa RP, et al. ISPAD Clinical Practice Consensus Guidelines 2018:Microvascular and macrovascular complications in children and adolescents[J]. Pediatr Diabetes, 2018, 19 (Suppl 27): 262-274. |
| [29] | Hainsworth DP, Bebu I, Aiello LP, Sivitz W, et al. Risk factors for retinopathy in type 1 diabetes: The DCCT/EDIC Study[J]. Diabetes Care, 2019, 42(5): 875-882. |
| [30] | Herskin CW, Olsen BS, Madsen M, et al. Screening for retinopathy in children with type 1 diabetes in Denmark[J]. Pediatr Diabetes, 2020, 21(1): 106-111. |
| [31] | Gomes MB, Calliari LE, Conte D, et al. Diabetes-related chronic complications in Brazilian adolescents with type 1 diabetes. A multicenter cross-sectional study[J]. Diabetes Res Clin Pract, 2021, 177: 108895. |
| [32] | Liu S, Kuja-Halkola R, Larsson H, et al. Neuro developmental disorders, glycemic control, and diabetic complications in type 1 diabetes: a nationwide cohort study[J]. J Clin Endocrinol Metab, 2021, 106(11): e4459-e4470. |
| [33] | Ling P, Zhang Y, Luo SH, et al. Glycemic control and its associated factors in children and adolescents with type 1 diabetes mellitus[J]. Zhonghua Yi Xue Za Zhi, 2018, 98(46): 3762-3766. |
| [34] | Chen X, Pei Z, Zhang M, Xu Z, et al. Glycated hemoglobin (HbA1c) concentrations among children and adolescents with diabetes in middle- and low-income countries, 2010-2019: a retrospective chart review and systematic review of literature[J]. Front Endocrinol (Lausanne), 2021, 12: 651589. |
| [35] | American Diabetes Association Professional Practice Committee. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022[J]. Diabetes Care, 2022, 45(Suppl 1): S17-S38. |
| [36] | World Health Organization. Classification of diabetes mellitus[EB/OL]. Geneva. 2019. https://www.who.int/publications-detail/classification-of-diabetes-mellitus. |
| [37] | 中国医师协会内分泌代谢科医师分会, 国家代谢性疾病临床医学研究中心. 糖尿病分型诊断中国专家共识[J]. 中华糖尿病杂志, 2022, 14(2): 120-139. |
| [38] | American Diabetes Association Professional Practice Committee. Children and Adolescents: Standards of Medical Care in Diabetes-2022[J]. Diabetes Care, 2022, 45(Suppl 1): S208-S231. |
| [39] | 中华医学会儿科学分会内分泌遗传代谢学组, 中华儿科杂志编辑委员会. 中国儿童1型糖尿病标准化诊断与治疗专家共识(2020版)[J]. 中华儿科杂志, 2020, 58(6): 447-454. |
| [40] | Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range[J]. Diabetes Care, 2019, 42(8): 1593-1603. |
| [41] | Forlenza GP, Pinhas-Hamiel O, Liljenquist DR, et al. Safety evaluation of the MiniMed 670G system in children 7-13 years of age with type 1 diabetes[J]. Diabetes Technol Ther, 2019, 21: 11-19. |
| [42] | Cengiz E. Automated insulin delivery in children with type 1 diabetes[J]. Endocrinol Metab Clin North Am, 2020, 49(1): 157-166. |
| [43] | Chen S, Du K, Zou C. Current progress in stem cell therapy for type 1 diabetes mellitus[J]. Stem Cell Res Ther, 2020, 11(1): 275. |
| [44] | von Scholten BJ, Kreiner FF, Gough SCL, et al. Current and future therapies for type 1 diabetes[J]. Diabetologia, 2021, 64(5): 1037-1048. |
/
| 〈 |
|
〉 |
